A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT...
Main Authors: | Liggins, A, Lim, S, Soilleux, E, Pulford, K, Banham, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
by: Liggins, A, et al.
Published: (2010) -
Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
by: Campbell, A, et al.
Published: (2010) -
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
by: Cooper, C, et al.
Published: (2006) -
A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
by: Liggins, A, et al.
Published: (2004) -
The expression of phosphorylated KDR in haematological malignancies
by: Pillai, G, et al.
Published: (2003)